NLRP3 Activation With Bisphosphonate Use and the Risk of Incident Age-Related Macular Degeneration
Bisphosphonate use increases AMD risk, while NLRP3 inhibitors mitigate this effect. These findings support the hypothesis that the NLRP3 inflammasome is involved in AMD pathogenesis and represents a potential therapeutic target.
Authors
- Tammy H. Cummings (ORCID: https://orcid.org/0000-0001-7978-7157)
- S. Scott Sutton
- Joseph Magagnoli (ORCID: https://orcid.org/0000-0002-8568-0097)
- James W. Hardin (ORCID: https://orcid.org/0000-0003-0506-5500)
- Jayakrishna Ambati (ORCID: https://orcid.org/0000-0003-1622-6365)
Institutions
- University of South Carolina (US)
- Columbia VA Health Care System (US)
- Dorn Research Institute (US)
- University of Virginia (US)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1167/iovs.66.3.32
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00